Overview of Recent Updates in Bispecific Therapy in R/R MM

Opinion
Video

The panel discusses the benefits of having multiple BCMA-targeting bispecifics available for patients with relapsed/refractory multiple myeloma.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Discuss similarities/differences in mechanism of action, key efficacy endpoints and safety data:
      • Teclistamab 
      • MajesTEC-1 (NEJM 2022)
      • MajesTEC-1 Long-term Follow-up (ASCO 2024)